Constantiam Biosciences is at the forefront of genomic medicine, focusing on the elucidation of genetic variation to enhance precision diagnostics and therapeutics. Their innovative technologies include the RareScan™ platform, which employs Deep Mutational Scanning (DMS) to classify variants of uncertain significance (VUS) and predict drug responses. This approach not only improves patient access to treatments for rare diseases but also supports drug development efforts. Additionally, the Genable™ platform revolutionizes drug target discovery by integrating human genetic data with massively multiplexed experiments and machine learning, enabling the prioritization of high-confidence targets that accelerate the discovery process while reducing costs.

Another key technology is StratiVar, which optimizes clinical trial enrollment by assessing the susceptibility of single amino acid variations in targeted proteins to novel therapeutics. This is achieved through drug-specific DMS, providing actionable insights such as drug-sensitivity profiles and predicted patient responses. Furthermore, MAVEvidence serves as a vital resource for the clinical genetics community, offering comprehensive curation and analysis of functional evidence from high-throughput studies of genetic variants, ultimately enhancing productivity and efficiency in genetic research.

United States

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

Constantiam Biosciences

Company Details